In the context of small cell lung cancer (SCLC), these TP53 GOF mutations contribute to poor treatment efficacy by fostering genomic instability, enhancing migratory and invasive capacities, and conferring multi-faceted therapy resistance [20–22]. This evidence concerns the gene TP53 and small cell lung carcinoma.